Join the 'Ixazomib' group to help and get support from people like you.
Posted 6 Jun 2016 by Drugs.com
MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more
Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Rituxan, Lung Cancer, Colorectal Cancer, Isotretinoin, Claravis
Posted 20 Nov 2015 by Drugs.com
FRIDAY, Nov. 20, 2015 – Ninlaro (ixazomib), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat people with multiple myeloma who have had at least one prior treatment with a different therapy. Multiple myeloma is a type of cancer that forms in infection-fighting white blood cells produced in bone marrow. Symptoms include a weakened immune system and bone and kidney problems. Ninlaro, from a class of drugs called proteasome inhibitors, is designed to block enzymes that spur the growth and survival of multiple myeloma cells, the FDA said Friday in a news release. Almost 27,000 cases of multiple myeloma will be diagnosed in the United States this year, and more than 11,000 people are projected to die from it, the FDA said, citing the National Cancer Institute. Ninlaro is approved in combination with another multiple myeloma drug, ... Read more
Posted 20 Nov 2015 by Drugs.com
November 20, 2015 – Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, produce an abnormal protein and push out other healthy blood cells from the bone marrow. The disease may result in a weakened immune system and cause other bone or kidney problems. The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States this year. “As we learn more about the underlying biology of multiple myeloma, we are encouraged to see the development of new ways to treat this disease,” said Richard Pa ... Read more